35.5/100,000 for African Americans compared with Caucasians (2) . According to small observational trials, cardiac involvement occurs in 5% of patients with systemic sarcoidosis (3) . However, autoptic studies exhibit cardiac affection in up to 64% of cases (4), insinuating a substantial underrecognition. After respiratory failure, sarcoidal heart involvement constitutes the second most common cause of death in sarcoidosis worldwide (5) , and the leading cause of sarcoidal death in Japan (6) . Its clinical presentation is determined by lesions' localization and predominantly comprises arrhythmias (7) and dilated cardiomyopathy up to heart failure (8) . Nonetheless, sudden death can occur without prior cardiac events or symptoms, indicating the challenging necessity of establishing adequate evaluative modalities that allow for a timely diagnosis and effective monitoring of cardiac sarcoidosis.
In a cohort of 81 patients with extracardiac sarcoidosis, late gadolinium enhanced cardiac magnetic resonance (LGE-CMR) identified cardiac involvement in 26% that was associated with major cardiac adverse events (9) . The study population comprised 73% African Americans who are known to exhibit a higher incidence of sarcoidosis than other ethnic groups.
The aim of this prospective study of a largescaled sarcoidosis cohort was to determine the prevalence of cardiac sarcoidal affection in a primary Caucasian population by use of cardiovascular magnetic resonance imaging (CMR), to differentiate in dependence on the CMR-stated disease activity and with correlate the results to established non-invasive tests in order to assess their predictive value.
Methods
191 consecutive patients aged 18 to 70 with a history of histologically proven sarcoidosis were eligible for this prospectively conducted clinical cohort trial. Study population was composed of outpatients receiving treatment at the University Hospital's Department of Pneumology (Bonn, Germany) and patients recruited from a nationwide sarcoidosis selfhelp association. Exclusion criteria comprised presence of implanted metallic devices and foreign bodies, pregnancy and claustrophobia. To prevent occurrence of gadolinium-induced nephrogenic systemic fibrosis (10), we additionally excluded patients presenting with a glomerular filtration rate < 30 ml/min, acute kidney injury or receiving dialysis. Informed consent was obtained from each patient.
Prior to the CMR study, standardized questionnaire-based clinical evaluation on any time occurrence of cardiac symptomatology, cardiac comorbidities and sarcoidal findings was performed. In case of CMR-based diagnosis of cardiac sarcoidosis, locally treated patients were re-examined by CMR at a six-month interval and their medication was adjusted at local physician discretion. Participants recruited through the sarcoidosis association received no local CMR-follow up.
Electrocardiogram and transthoracic echocardiography
All patients treated at the local pneumological department systematically underwent 12-lead electrocardiogram (ECG), Holter monitoring and transthoracic echocardiography as part of their routine medical care. Electro-and echocardiographic features of self-help association-recruited patients were assessed by collection from their medical reports.
In line with the Japanese Ministry of Health and Welfare Guidelines (JMHWG) on sarcoidosis, revised in 2009 (11), which in turn form the basis of the recently published German consensus paper on diagnostics and therapy of cardiac sarcoidosis (12) , pathological electro-and echocardiographic findings were pre-defined as depicted in Table 1 .
Laboratory testing
Immediately prior to CMR conduction, blood sampling was performed and encompassed biomarkers that have previously been reported to correlate with sarcoidosis activity or cardiac injury: a complete blood-cell count, serum angiotensin converting enzyme (ACE), soluble interleukin-2 receptor (sIL-2R), C-reactive protein (CRP), cardiac troponin I (cTnI) and plasma N-terminal pro-BNP (NTproBNP) were assessed.
Pulmonary function tests
Testing comprised spirometry, bodyplethysmography and determination of diffusion capacity for carbon monoxide. Parameters were assessed in absolute terms and in percentages of the predicted values, in conformity with the European Respiratory Society guidelines (13) .
Cardiovascular magnetic resonance imaging
All cardiovascular CMR studies were acquired on a clinical 1.5T scanner (1.5T Intera, Philips Healthcare, Best, The Netherlands), equipped with a cardiac phased-array coil. The imaging protocol followed recommendations on standardized cardiovascular magnetic resonance imaging (14) . After acquisition of scout images for determining the standard cardiac views, cine CMR was carried out. For visualization of myocardial oedema, fat-suppressed T2-weighted black-blood turbo spin echo sequences were acquired in the short axis orientation. Dynamic T1 imaging was performed for assessment of early relative contrast enhancement as previously described (15) . Delayed enhancement imaging covering the standard cardiac axes was performed 12-15 minutes after gadolinium injection (0.1 mmol/kg gadolinium-DTPA). Total examination time was 45 to 60 minutes. Assignment of late enhancing lesion localization was performed in accordance with the American Heart Association's standardized myocardial segmentation and nomenclature (16) . Two experienced radiologists, blinded to all clinical data, independently evaluated CMR images. In case of discordant results, the studies were reassessed to reach consensus.
Statistical analysis
Descriptive statistics are presented as absolute numbers and percentages or means (±SD), when appropriate. CMR-diagnosed cardiac sarcoidosis was correlated to clinical data, serological, electrocardiographic, echocardiographic and pulmonary parameters by use of Pearson's χ² test -in case of categorical variables -, or unpaired t-test, when continuous parameters were compared. A p-value < 0.05, resulting of 2-tailed tests, was considered threshold for statistical significance. Statistical analyses were performed using SPSS Statistics 22 software (IBM, Armonk, NY, USA).
Results
From June 2011 till September 2013, 191 patients with histologically proven sarcoidosis, meeting the inclusion criteria, were identified for possible participation in the study. Of these, one patient was excluded due to obesity-driven technical CMR conduction difficulties. A further two excluded patients were kidney transplanted and run risk of developing gadolinium-induced nephrogenic systemic fibrosis, albeit GFR values were within the normal range.
Demographic characteristics and clinical data of the enrolled 188 patients are summarised in Table 2 . Data comparison based upon the different patient proveniences (local pneumological department and nationwide self-help association) is outlined in Table 3 , revealing no intercohortal differences in distribution of characteristics with the sole exception of a predominance of female patients in the association-recruited cohort (66.7% versus 48.3%, p=0.01).
Study population offered a slight predominance of women (55.3%, n=104) and exhibited a mean age of 52±13 years, with Caucasian origin representing 97.3% (n=183) of the entire population Data are presented as mean ± SD or total number and percentage (in parentheses). *Cardiac symptoms refer to any time occurrence, not to presence at CMR conduction. Abbreviations: NYHA = New York Heart Association; FEV1 = forced expiratory volume in 1 second; IVC = inspiratory vital capacity DLCO = diffusion capacity for carbon monoxide; VA = alveolar volume provenance. Mean duration since diagnosis of sarcoidosis averaged 114 months (median 73 months). Pulmonary sarcoidal involvement was present in 64.9%; main extrapulmonary manifestation is depicted in Table 2 . The percentage of patients in whom a cardiac involvement had already been diagnosed prior to CMR conduction, solely accounted for 0.5% (n=1). Löfgren syndrome was present in 5.3% of patients, none of whom exhibited cardiac sarcoidal manifestation.
CMR identified cardiac sarcoidosis (CS) based on the presence of early relative gadolinium enhancement, regional oedema or late gadolinium enhancement in 15.4% of the whole study population (Figure 1 ). Correlation analyses evinced no differences in CS prevalence in terms of ethnicity (p=0.93). Pearson's χ² test revealed a significant dependence of CS occurrence on concomitant lymph node affection (p=0.013), whereas there was no association between CS and other sarcoidal organ involvement.
Distribution analysis of most late enhancing lesions identified mid to basal inferoseptal ventricular areas to be predilectively affected (Figure 2 ), a result that is in line with prior reports (9, 17) . Differentiation as a function of disease activity resulted in a distribution of 9% (n=17) offering acute, inflammatory changes, 5.9% (n=11) having myocardial scar and 0.5% (n=1) presenting both acute and chronic phase cardiac abnormalities. CMR-follow up study was carried out in 12 out of 29 patients (41.4%). In four patients, medical immunosuppressive treatment was meanwhile escalated (steroidal dosage increase, addition of azathioprine), resulting in a regredience of early relative gadolinium enhancement in all four patients. None of the eight remaining patients without medication adjustment developed aggravation of CMR-stated cardiac affection: 7 patients presented consistent findings, Data are presented as mean ± SD or total number and percentage (in parentheses).
while 1 patient showed spontaneous remission of early relative contrast enhancement. CMR-assessed global cardiac function parameters and volumes are given in Table 4 and revealed significant correlation of CS-status with mean left ventricular ejection fraction (LVEF) and diastolic interventricular septal thickness (IVSD) (p=0.03 and p=0.03, respectively; Table 4 ).
Electro-and echocardiographic data were available for 146 (77.7%) and 132 patients (70.2%), respectively. 12-lead ECG changes that were identified to correlate with the presence of cardiac sarcoidosis, comprised third-degree atrioventricular block (p=0.02), pathological Q-waves (p=0.02), incomplete left bundle branch block (p=0.02) and QRS fragmentation (p=0.02). Holter monitoring evidenced a burden of > 1000 ventricular extrasystoles/24h to be significantly associated with CS (p=0.002).
In terms of echocardiographic assessment, diastolic dysfunction ≥ I° and reduction of LVEF <50% were found to be the only echocardiographic abnormalities that correlated with cardiac sarcoidosis (p=0.04 and p=0.02, respectively).
By laboratory analysis, none of the tested parameters showed significant distributive differences between the CS-positive and the CS-negative cohorts (Table 4) . Likewise, pulmonary function parameters exhibited no association with CS and were similar in both groups.
Discussion
The present study prospectively analysed the frequency of CMR-detected cardiac sarcoidal involvement in a large, almost exclusive Caucasian study population with histologically proven sarcoidosis. Prevalence of CMR-based cardiac affection was identified to account for 15.4%. The predictive value of parameters assessed by standard clinical testing and specified by the current guidelines emerged to be moderate.
Despite lacking gold standard, CMR-guided diagnosis of cardiac sarcoidosis by assessment of late gadolinium enhancement (LGE) constitutes the favoured diagnostic approach. Patel et al. compared LGE-CMR to the then valid consensus criteria and identified LGE-stated cardiac sarcoidosis in 26% of sarcoidal patients (9) . Comparison with our data emphasizes a substantially higher CS prevalence in Patel's cohort. This discrepancy may be due to Patel´s predominantly African American study population of 73% which in turn is known to experience a higher sarcoidosis occurrence that can possibly be extrapolated to cardiac affection. In a Dutch study cohort (18), Smedema et al. complemented the 1993 modified Japanese Ministry of Health and Welfare Guidelines (JMHWG) (19) with LGE-CMR for diagnosis of CS and determined a LGE-CMRbased CS prevalence of 32.8%. This discrepancy from our finding can primarily be traced back to Smedema´s inclusion of a substantial portion of patients presenting cardiac symptomatology at CMR conduction that in turn augmented the probability of diagnosing CS. Moreover, our study population comprised a >3-fold larger number of patients, indicating a minor susceptibility to statistical outliers. In contrast to the above mentioned studies that almost exclusively analysed LGE in CMR, we incorporated T2-weighted imaging as well as early relative gadolinium enhancement. Whereas LGE assesses predominantly nonviable-fibrotic or necrotictissue and is indicative of poor prognosis (20) , T2 imaging and early relative gadolinium enhancement detect acute inflammatory injury resulting in myocardial oedema or hyperperfusion. Schulz-Menger et al. previously reported correlation of early relative contrast enhancement in patients with suspected cardiac sarcoidal involvement that normalized after steroid treatment (15) . In a population of 16 patients presenting systemic sarcoidosis, Shimada et al. identified early enhancing lesions that were likewise regredient after glucocorticoid therapy (21) . Both studies imply the value of early local and global contrast enhancement in viable myocardium that may mainly occurs in early CS stages. In equal manner to the above depicted courses, we objectified early relative enhancement regression under steroid treatment which permits application of early gadolinium imaging for guidance of medical therapeutic management. Quantitative T1 mapping has now emerged as a robust clinical tool for myocardial tissue characterization and may be superior to assessment of relative early gadolinium enhancement (22) . However, its value for sarcoidosis evaluation needs yet to be established.
Over a ten-year period, Greulich and colleagues enrolled and examined 155 patients with clinically suspected cardiac sarcoidosis by CMR-guided LGE-assessment and ascribed prognostic relevance to the presence of LGE (20) . Contrary to Greulich´s study cohort, we presupposed biopsy-proven sarcoidosis for study inclusion, while Greulich accepted a clinical criteria-based diagnosis of sarcoidosis. Moreover, we consciously included all sarcoidal patients irrespectively of any cardiac symptomatology or previously detected cardiac affection in order to prevent preselection and provide insights into actual CS prevalence in the general sarcoidal population, even in patients lacking cardiac symptoms. A further difference to the above mentioned study constitutes our complemental assessment of early relative contrast enhancement that enabled us to evaluate myocardial changes and their medical influenceability in the early phases of CS.
Clinical manifestation of CS covers the entire range of silent course up to sudden cardiac death. Given its frequently prognosis-limiting nature, the necessity for a precise diagnostic methodology to define CS presence and guide CS therapy arises. Principally based on the JMHWG, revised in 2009 and serving as a global CS diagnostic standard (11), the German Respiratory and Cardiac Societies recently published a consensus paper that provides diagnostic and therapeutic algorithms for CS (12) . In previously diagnosed extracardiac sarcoidosis, it suggests a stepwise approach with the initial evaluation includ- LGE-CMR. The sole echocardiographic abnormalities that exhibited significant correlation with CMR findings were presence of diastolic dysfunction graded ≥ I and reduction of left ventricular ejection fraction (LVEF) <50%; the latter is integrated in the CS baseline assessment of the JMHWG and the German guidelining statement. Nonetheless, neither interventricular basal septum thinning, nor wall motion abnormalities, nor valvular dysfunction -all of which represent further established JMHWG criteria -were linked to CMR-stated CS. Vice versa, recognition of cardiac involvement by application of German consensus paper that envisages a stepwise approach and CMR-or FDG-PET-conduction under the premise that prior ECG-and TTE-assessment ascertains at least one pathological finding, would have solely permitted identification of 48.3% (14 out of 29 patients) of the present CMR-diagnosed cardiac sarcoidosis cases. Comparably, appliance of revised JMHWG in our cohort would have enabled us to only diagnose one affected patient owing to endomyocardial biopsy. In case of lack or incongruity of cardiac histology, the JMHWG-based CS diagnostic pathway would have failed to detect 28 out of 29 presently diagnosticated CS cases, admittedly with the restriction that we did not perform radionuclide myocardial imaging. In due consideration of the above mentioned crucial CS-underrecognition, necessity of up valuing CMR in the CS diagnostic approach becomes evident.
The value of laboratory blood tests in CS has been indeterminate. Date and colleagues described plasma brain natriuretic peptide (BNP) to be significantly elevated in patients with CS, compared to a pulmonary sarcoidosis cohort, and ascribed diagnostic utility to this biomarker (24) . However, these authors based their diagnosis of CS solely on the 1993 published JMHWG (19) which in turn have been demonstrated to be significantly less sensitive for CS-detection than CMR (9) and might therefore have contributed to a bias in their patient group assignment in an already small numbered total cohort of 21 participants.
In our study, none of the tested laboratory parameters revealed significant correlation with CMRbased CS, not even if only cases with acute inflammed tissue damage were examined. Established laboratory values for extracardiac sarcoidal inflammatory processes (sIL-2R) and granulomatous burden (ACE) lacked association with CS diagnosis or severity, a finding that to our knowledge is first described in the present study. Laboratory testing is conclusively non-diagnostic in CS and thereby consistent with the current diagnostic standards.
There are several limitations to be considered. Our study population was composed of two different patient provenances comprising outpatients treated by the local pneumological department and patients linked to the nationwide sarcoidosis self-help association. However, except for gender distribution, data comparison did not reveal statistically significant intercohortal differences in demographic characteristics. In respect of availability of ECG and TTE we have to recognize that only the locally treated patient group exhibited complete database, whereas the percentage of association-recruited patients presenting 12-lead ECG, ambulatory ECG monitoring and TTE was 41.7%, 12.5% and 22.2%, respectively.
Despite the large study population size, the number of CMR-detected CS encompassing both early and late disease stages was small, limiting an extrapolation of the observed correlation of electroand echocardiographic abnormalities to the different disease stages. Although present CS-rate distribution did not exhibit significant interethnic differences, it is primarily ascribable to the limited number of Non-Caucasian participants that in turn is due to pour study concept of investigating CS in a mainly Caucasian cohort.
Conclusively, with a prevalence of 15.4%, CMR-detected cardiac sarcoidal involvement in a primary Caucasian sarcoidosis patients exceeds the observationally reported cardiac affection three times over. However, cardiac involvement as detected by clinical standard testing as well as magnetic resonance imaging appears to be less frequent in the presently examined Caucasian sarcoidosis population than in previously studied Japanese or African American cohorts.
With the intend to evaluate the prognostic potential of CMR results, additional longitudinal follow-up of this study cohort for evaluating the occurrence of arrhythmic events or progressive heart failure would help to definitely determine the significance of CMR in CS and would permit a timely initiation of medical or device therapeutic approaches.
